A highly selective inhibitor of IκB kinase, BMS‐345541, blocks both joint inflammation and destruction in collagen‐induced arthritis in mice
Open Access
- 11 September 2003
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (9) , 2652-2659
- https://doi.org/10.1002/art.11131
Abstract
Objective The transcription of several cytokines, cell adhesion molecules, and enzymes involved in the inflammatory and destructive mechanisms of rheumatoid arthritis is dependent on nuclear factor κB (NF-κB). Because IκB kinase (IKK) is critical in transducing the signal-inducible activation of NF-κB, we examined whether the highly selective and orally bioavailable IKK inhibitor BMS-345541 is efficacious against collagen-induced arthritis (CIA) in mice. Methods Arthritis in DBA/1LacJ male mice was induced by subcutaneous immunization with bovine type II collagen on day 0 and day 21. BMS-345541 was administered perorally daily, either prophylactically (before disease onset) or therapeutically (after disease onset). Clinical assessment of the incidence and severity of disease was conducted throughout the study, and histologic evaluation was performed at the time of study termination (day 42). Results When administered prophylactically, BMS-345541 (in a dose range of 10–100 mg/kg) was effective, in a dose-dependent manner, in reducing the incidence of disease and inhibiting clinical signs of disease. Histologic evaluation of the joints showed that both inflammation and joint destruction were blocked by the IKK inhibitor. Message levels of interleukin-1β in the joints were also dose-dependently inhibited in the mice that received BMS-345541. Dose-dependent efficacy in terms of both disease severity and histologic end points was observed with the therapeutic dosing regimen of BMS-345541, with use of the 100-mg/kg dose resulting in resolution of disease. Conclusion IKK plays a key role in CIA in mice, and inhibitors of this enzyme represent a promising target for the development of novel agents to treat rheumatoid arthritis and other inflammatory diseases. BMS-345541 represents the first example of an inhibitor of IKK that has antiinflammatory activity in vivo.Keywords
This publication has 23 references indexed in Scilit:
- BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in MiceJournal of Biological Chemistry, 2003
- Missing Pieces in the NF-κB PuzzleCell, 2002
- IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland DevelopmentCell, 2001
- Inhibitor of nuclear factor ?B kinase ? is a key regulator of synovial inflammationArthritis & Rheumatism, 2001
- Animal Models of Arthritis: Relevance to Human DiseaseToxicologic Pathology, 1999
- Regulation of IκBβ DegradationPublished by Elsevier ,1997
- I kappa B epsilon, a novel member of the Ikappa B family, controls RelA and cRel NF-kappa B activityThe EMBO Journal, 1997
- Role of I Bα Ubiquitination in Signal-induced Activation of NF- B in VivoJournal of Biological Chemistry, 1996
- Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IkB-αJournal of Biological Chemistry, 1996
- Structure, Regulation and Function of NF-kappaBAnnual Review of Cell Biology, 1994